Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Indolent Lymphoproliferative Disorders”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00240565
What this trial is testing

Tositumomab And Iodine I 131-Tositumomab In Patients With Relapsed Indolent Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma, Non-Hodgkin
GlaxoSmithKline 93
Early research (Phase 1)Study completedNCT00001512
What this trial is testing

Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines

Who this might be right for
B Cell LymphomaFollicular LymphomaLymphoma
National Cancer Institute (NCI) 42
Testing effectiveness (Phase 2)WithdrawnNCT00003663
What this trial is testing

Rituximab and Dexamethasone in Treating Patients With Recurrent or Refractory Indolent Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Hoag Memorial Hospital Presbyterian
Testing effectiveness (Phase 2)Study completedNCT00220285
What this trial is testing

Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma

Who this might be right for
Non-Hodgkin's LymphomaLymphoma, B-CellLymphoma, Low-Grade
Bayer 45
Testing effectiveness (Phase 2)Active Not RecruitingNCT03198026
What this trial is testing

Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas

Who this might be right for
Non-Hodgkin's LymphomaAnn Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueAnn Arbor Stage II Follicular Lymphoma+16 more
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University 29
Early research (Phase 1)Study completedNCT01705847
What this trial is testing

A Phase 1b Study Evaluating GS-9820 in Subjects With Lymphoid Malignancies

Who this might be right for
Lymphoid Malignancies
Gilead Sciences 39
Large-scale testing (Phase 3)WithdrawnNCT00551239
What this trial is testing

Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma

Who this might be right for
LeukemiaLymphoma
CTI BioPharma
Testing effectiveness (Phase 2)Study completedNCT01153971
What this trial is testing

Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas

Who this might be right for
Non-Hodgkin's Lymphoma
Hoffmann-La Roche 47
Testing effectiveness (Phase 2)Study completedNCT00493467
What this trial is testing

Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas

Who this might be right for
Lymphoma
M.D. Anderson Cancer Center 31
Large-scale testing (Phase 3)Study completedNCT01609010
What this trial is testing

MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Who this might be right for
Lymphoma
Hoffmann-La Roche 313
Testing effectiveness (Phase 2)Study completedNCT00509379
What this trial is testing

Non-randomized Safety Study With Bortezomib/Rituximab in Relapsed/Refractory Indolent Lymphoma

Who this might be right for
LymphomaNon-Hodgkin Lymphoma
Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie 48
Testing effectiveness (Phase 2)Study completedNCT00005579
What this trial is testing

Dolastatin 10 in Treating Patients With Indolent Lymphoma, Waldenstrom's Macroglobulinemia, or Chronic Lymphocytic Leukemia

Who this might be right for
LeukemiaLymphoma
University of Vermont
Not applicableStudy completedNCT00398372
What this trial is testing

Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment

Who this might be right for
Lymphoma, Non-HodgkinLymphomas: Non-HodgkinLymphomas: Non-Hodgkin Cutaneous Lymphoma+6 more
Stanford University 500
Testing effectiveness (Phase 2)UnknownNCT00258336
What this trial is testing

Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Favrille 56
Large-scale testing (Phase 3)WithdrawnNCT02576275
What this trial is testing

Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)

Who this might be right for
Indolent Non-Hodgkin's LymphomaFollicular LymphomaSmall Lymphocytic Lymphoma+1 more
SecuraBio
Not applicableEnded earlyNCT02273856
What this trial is testing

Multicentre Registry of Treatments and Outcomes in Patients With Chronic Lymphocytic Leukaemia (CLL) Or Indolent Non Hodgkin's Lymphoma (iNHL)

Who this might be right for
Indolent Non Hodgkin's Lymphoma (iNHL)Chronic Lymphocytic Leukaemia (CLL)
Astellas Pharma International B.V. 25
Not applicableLooking for participantsNCT06822829
What this trial is testing

Multicenter Retrospective Observational Study of Relapsed Diffuse Large B-Cell Lymphoma Presenting as Indolent Lymphoma

Who this might be right for
Diffuse Large B Cell Lymphoma (DLBCL)Indolent B-Cell LymphomasIndolent B Cell Lymphoma
Azienda USL Reggio Emilia - IRCCS 50
Testing effectiveness (Phase 2)Study completedNCT00085696
What this trial is testing

VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma

Who this might be right for
B-Cell LymphomaFollicular LymphomaMarginal Lymphoma
Millennium Pharmaceuticals, Inc. 66
Testing effectiveness (Phase 2)Ended earlyNCT00768339
What this trial is testing

A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas

Who this might be right for
Leukemia, Lymphocytic, Chronic, B-CellLymphoma, B-Cell
Aegera Therapeutics 25
Testing effectiveness (Phase 2)Ended earlyNCT02898259
What this trial is testing

Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma

Who this might be right for
B Cell LymphomaLymphoma
Brian Hill 19
Next Page